drugset / Trial / NCT04249232

Summary

This is a prospective randomized, double-blinded, placebo-controlled, phase 2, three-month study of the efficacy of abaloparatide in postmenopausal women and men ≥ 50 years of age with acute fractures of the pelvis (n=78). The primary outcome is CT image based evidence of fracture healing. The secondary aims are pain and physical performance measures at 3 months. This study will be extended with 9 months of open label abaloparatide to determine if any potential differences between the placebo and abaloparatide groups during the 3 months of treatment are evident and persist over time, even in patients who use abaloparatide after the three-month placebo controlled intervention.

Timeline

Start
2020-09-17
Primary completion
2024-04-25
Completion
2024-04-25

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator Abaloparatide Peptide 80 ug Subcutaneous

Indications

No indication recorded.